A patient may have been exposed to the virus without ever experiencing symptoms and a blood test is not always able to determine whether the patient has been exposed to the virus.
From an athletes perspective, I also wont consider using it until it has been approved by anti-doping authorities
Risk of Regaining Weight After Stopping : Many people regain weight if they stop taking GLP-1 drugs, as appetite and cravings can return
The cost of replacing a vial of semaglutide is always less than the cost of injecting compromised medication
DPP-4 inhibitor therapy has been shown to reduce the risk for atherosclerosis and CAD through both glycemic control and direct effects on the atherosclerotic process, including atherosclerosis or plaque stability, and this topic has been addressed in recent reviews [11, 14]
A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline
